Brought to you by 
Ferring and Enteris to develop oral version of injectable peptide therapeutic
31 Jan 2023
Executive Summary
US based Enteris BioPharma Inc. licensed its oral drug delivery technologies to Swiss-based Ferring Pharmaceuticals AS in order to develop an oral formulation of one of Ferring's peptide-based therapeutics.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ferring and Enteris to develop oral version of injectable peptide therapeutic
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice